Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from SCRIP

22:08 EDT 23rd May 2018 | BioPortfolio

Here are the most relevant search results for "SCRIP" found in our extensive news archives from over 250 global news sources.

More Information about SCRIP on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about SCRIP for you to read. Along with our medical data and news we also list SCRIP Clinical Trials, which are updated daily. BioPortfolio also has a large database of SCRIP Companies for you to search.

Showing News Articles 1–25 of 3,100+ from SCRIP

Wednesday 23rd May 2018

Merck's Stellar Keytruda Squamous Lung Cancer Data Refute Naysayers

In Phase III KEYNOTE-407 of squamous NSCLC, Keytruda/chemo combo shows overall survival benefit, which was reassuring news for doctors –...   

Esperion Posts Positive Phase III Bempedoic Acid Results, But Future Fixed-Dose Data Are Key

Esperion reported positive results from the third of five Phase III studies expected to read out this year, but data...   

Opioid Withdrawal Treatment Claims Spur FDA's Latest Kratom Warnings

Cara’s Partnership With Vifor Fresenius Provides Validation For Pruritis Drug Korsuva

A Vifor Fresenius joint venture will market Korsuva for CKD-associated pruritis to Fresenius dialysis centers in Europe, and also will...  

PhRMA, BIO Mum On Trump’s Tariffs

While pressing the US trade representative for stronger IP protection, groups representing the brand biopharma sector remain silent on the...   

Generics, OTC AND API Groups Object To Proposed US Tariffs On Goods From China

AAM, CHPA, SOCMA and BPTF agree that proposed 25% tariffs on pharmaceuticals and APIs from China is a bad idea...    

Systemic Exposure Data A MUsT For OTC Monograph Sunscreens, Other Topical Drugs In FDA Draft Guidance

Challenges posed by FDA-advised maximal usage trials have been the bane of OTC sunscreen and antimicrobial drug ingredient sponsors recently...   

High Court Won’t Take Up Off-Label Case; Other FCA Issues On Docket

While the Supreme Court announced this week that it won’t hear a case related to off-label billings, other False Claims...    

Severe Asthma Market Snapshot: A Competitive Therapy Area That Will Test Payers' Influence

Several biologic drugs are now available for the 10% of asthma patients with severe uncontrolled disease, and Dupixent could join...   

Dupixent Shines At ATS, But Experts Question Which Novel Biologic Physicians Will Choose

Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will...   

Apotex Bags First Biosimilar Neulasta, Plans To Undercut Amgen In Canada By 25%

Apotex is hoping to sell its biosimilar version of Amgen’s Neulasta at a 25% discount in Canada after gaining approval...   

EuroPCR 2018: Abbott's Tendyne Mitral Valve Shows Early Promise

Early data from Abbott's CE mark study of its mitral valve replacement technology Tendyne shows the device's potential in reducing...   

Gilead May Have Better Takeover Targets Than Tesaro

Gilead has once more been mentioned as a prospective acquirer of Tesaro, but analysts at Datamonitor Healthcare's PharmaVitae believe that...   

Cipla Sounds The Bugle On US Respiratory Ambition

One "sizeable" respiratory inhalation launch in the US every year, starting next year, is what Cipla is targeting as it...   

EuroPCR 2018: Real-World TAVR Data Show Consistent Performance With Edwards, Abbott, And Medtronic's Systems

New real-world data on Edward Lifesciences real-world data for its transcatheter aortic valve replacement Sapien 3 valve are among the highlights from the early Hot...   

Euro PCR 2018: Real-World TAVR Data Show Consistent Performance With Edwards, Abbott, And Medtronic's Systems

New real-world data on Edward Lifesciences real-world data for its transcatheter aortic valve replacement Sapien 3 valve are among the highlights from the early Hot...   

Appointments: News From Sensei, DelMar, Seattle Genetics, Astellas, Galecto, Roivant Sciences And PDL BioPharma

This week's announcements include new CEOs at Sensei and DelMar, new chief medical officers at Seattle Genetics, Astellas Pharma, Galecto...   

Strides’ Founder Resumes Charge After Dismal Q4 Earnings

Strides Shasun founder Arun Kumar has moved back into the driver’s seat to focus on “course correction” after the Indian...    

Tuesday 22nd May 2018

BioMarin, Spark Hemophilia Gene Therapies Progress As Accelerated Approval Favors Their Indications

As updated Phase I/II results for BioMarin's hemophilia A and Spark's hemophilia B gene therapies were presented on May 22...   

Can Synthetic Vaccines Change The World’s Approach To Infectious Disease Crises?

Emerging Company Profile: Emergex Vaccines will use its nanobody technology to develop entirely synthetic immunizations against the world’s most concerning...    

QUOTED. May 23, 2018. Becky Fitzgerald.

US FDA is working with device firms and outside experts to adopt new tools for appraising companies' manufacturing capability and...   

Right-To-Try Bill Heads To White House, Putting Firms In Driver's Seat

Proponent says companies ready to use new expanded access pathway that US FDA will have essentially no involvement in.   

Right-To-Try Bill Heads To White House, Putting Firms In Drivers Seat

Proponent says companies ready to use new expanded access pathway that US FDA will have essentially no involvement in.   

Insys' Sublingual Buprenorphine Spray Fails At US FDA Panel, But Some Members See Future In Limited Role

Main concerns involved the delayed onset to meaningful pain relief and the safety signal of hypoxia.    

US FDA Advisory Panel Rebuffs Insys' Sublingual Buprenorphine Spray, But A Few Panelists Still See Use In Limited Role

Main concerns involved the delayed onset to meaningful pain relief and the safety signal of hypoxia.    


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks